



(11) **EP 4 177 902 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 71

(51) International Patent Classification (IPC):
G16H 20/10 ^(2018.01) **G16H 50/50** ^(2018.01)

(52) Cooperative Patent Classification (CPC):
G16H 50/50; G16H 20/10

(48) Corrigendum issued on:
29.05.2024 Bulletin 2024/22

(43) Date of publication:
10.05.2023 Bulletin 2023/19

(21) Application number: **21206570.0**

(22) Date of filing: **04.11.2021**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(71) Applicants:
• **Universität Basel**
4001 Basel (CH)
• **Universität Konstanz**
78464 Konstanz (DE)

(72) Inventors:
• **SZINNAI, Gabor**
4102 Binningen (CH)

- **KOCH, Gilbert**
88662 Überlingen (DE)
- **PFISTER, Marc**
3652 Hilterfingen (CH)
- **SCHROPP, Johannes**
78462 Konstanz (DE)
- **STEFFENS, Britta**
78464 Konstanz (DE)
- **BACHMANN, Freya**
78467 Konstanz (DE)

(74) Representative: **Schulz Junghans**
Patentanwälte PartGmbB
Großbeerenstraße 71
10963 Berlin (DE)

(54) **METHOD, SYSTEM AND COMPUTER PROGRAM FOR COMPUTATION OF OPTIMAL INDIVIDUAL DOSING REGIMEN, PARTICULARLY SUBJECT TO CLINICAL CONSTRAINTS**

(57) The present invention relates to a method for automatically determining an optimal individual dosing regimen of at least one drug for a patient suffering from a known disease, the optimal individual dosing regimen being optionally subject to at least one clinical constraint, wherein the method comprises the steps of: providing a mathematical model adapted to model a progression of said disease and an effect of the at least one drug on the progression of the disease, the model comprising individual model parameters associated with the patient; utilizing an empirical Bayesian estimation to automatically and numerically estimate the individual model parameters of the mathematical model utilizing patient data associated with the patient; automatically calculating an optimal individual dosing regimen for the mathematical model by solving an optimal control problem based on a

desired progression of the disease, the estimated individual model parameters, and an initial guess for the dosing regimen; and adjusting the optimal individual dosing regimen to optionally account for at least one clinical constraint to yield the optimal individual dosing regimen subject to said at least one clinical constraint.

EP 4 177 902 A8




Fig. 1